biostudies-literatureUnknown211(6)Smith JABellus Health, a GSK company<b>Rationale:</b> There is no broadly accessible treatment for patients with refractory chronic cough, a disease characterized by chronic cough that persists despite treatment for other cough-related etiologies or has no identified underlying cause. <b>Objectives:</b> SOOTHE (NCT04678206), a phase 2b, randomized, placebo-controlled trial, evaluated the efficacy and safety of P2X3 antagonist camlipixant in adults with refractory chronic cough (cough duration, ⩾1 yr; baseline awake cough frequency, ⩾25 coughs/h). <b>Methods:</b> After a single-blind, 16-day placebo run-in, patients were randomized (1:1:1:1) to receive camlipixant 12.5, 50, or 200 mg twice daily or placebo for 4 weeks. The primary endpoint was change from baseline to Day 28 in objective 24-hour cough frequency. Secondary endpAmerican journal of respiratory and critical care medicine1038-1048https://www.ebi.ac.uk/biostudies/studies/S-EPMC12180140biostudies-literatureCamlipixant in Refractory Chronic Cough: A Phase 2b, Randomized, Placebo-controlled Trial (SOOTHE).PMC12180140McGarvey LMorice AHBonuccelli CMBirring SSBlaiss MSGarin MSher MYang RSmith JALanouette SShaw JCarroll KJfalseCamlipixant in Refractory Chronic Cough: A Phase 2b, Randomized, Placebo-controlled Trial (SOOTHE).<b>Rationale:</b> There is no broadly accessible treatment for patients with refractory chronic cough, a disease characterized by chronic cough that persists despite treatment for other cough-related etiologies or has no identified underlying cause. <b>Objectives:</b> SOOTHE (NCT04678206), a phase 2b, randomized, placebo-controlled trial, evaluated the efficacy and safety of P2X3 antagonist camlipixant in adults with refractory chronic cough (cough duration, ⩾1 yr; baseline awake cough frequency, ⩾25 coughs/h). <b>Methods:</b> After a single-blind, 16-day placebo run-in, patients were randomized (1:1:1:1) to receive camlipixant 12.5, 50, or 200 mg twice daily or placebo for 4 weeks. The primary endpoint was change from baseline to Day 28 in objective 24-hour cough frequency. Secondary endp2025-01-01T00:00:00Z2025 Jun2026-06-03T07:46:52.284Z2026-04-26T03:10:07.602ZS-EPMC121801404004330210.1164/rccm.202409-1752OC